{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:01:00Z","timestamp":1783512060975,"version":"3.55.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hypereosinophilic syndrome (HES) is an extremely uncommon group of disorders. It rarely presents with coagulopathy without cardiac involvement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 33-year-old previously healthy male with no history of atopic disease presented with abdominal pain, hematochezia, peripheral eosinophilia as high as 10,000 eos\/\u00b5L, right and left portal vein, mesenteric, and splenic vein thrombi with ischemic colitis resulting in hemicolectomy and small bowel resection. Despite an extensive workup for primary and secondary etiologies of hypereosinophilia by hematology\/oncology, infectious disease, rheumatology and allergy\/immunology, no other clear causes were identified, and the patient was diagnosed with idiopathic HES. His eosinophilia was successfully treated with high-dose oral corticosteroids (OCS) and subsequently transitioned to anti-IL-5-receptor therapy with benralizumab. He has continued this treatment for over a year with no recurrence of eosinophilia or thrombosis while on benralizumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In patients with an unexplained coagulopathy and eosinophilia, eosinophilic disorders such as HES should be considered. Corticosteroid-sparing agents, such as benralizumab show promise for successfully treating these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13223-022-00666-2","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T13:03:23Z","timestamp":1647954203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hypereosinophilic\u00a0syndrome presenting as coagulopathy"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6751-7368","authenticated-orcid":false,"given":"Kestutis","family":"Aukstuolis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn J.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Altman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Ayars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"issue":"2","key":"666_CR1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12016-015-8506-7","volume":"50","author":"C Curtis","year":"2016","unstructured":"Curtis C, Ogbogu P. Hypereosinophilic syndrome. Clin Rev Allergy Immunol. 2016;50(2):240\u201351.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"666_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jaci.2010.03.035","volume":"126","author":"MM Crane","year":"2010","unstructured":"Crane MM, Chang CM, Kobayashi MG, Weller PF. Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol. 2010;126(1):179\u201381.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"666_CR3","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/ajh.25617","volume":"94","author":"W Shomali","year":"2019","unstructured":"Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2019;94(10):1149\u201367. https:\/\/doi.org\/10.1002\/ajh.25617.","journal-title":"Am J Hematol"},{"issue":"2","key":"666_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1053\/j.seminhematol.2012.01.002","volume":"49","author":"HU Simon","year":"2012","unstructured":"Simon HU, Klion A. Therapeutic approaches to patients with hypereosinophilic syndromes. Semin Hematol. 2012;49(2):160\u201370.","journal-title":"Semin Hematol"},{"issue":"6","key":"666_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.jaip.2017.08.001","volume":"5","author":"FL Kuang","year":"2017","unstructured":"Kuang FL, Klion AD. Biologic agents for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol Pract. 2017;5(6):1502\u20139.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"21","key":"666_CR6","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood.2019000518","volume":"134","author":"C Marx","year":"2019","unstructured":"Marx C, Novotny J, Salbeck D, Zellner KR, Nicolai L, Pekayvaz K, Kilani B, Stockhausen S, B\u00fcrgener N, Kupka D, Stocker TJ, Weckbach LT, Pircher J, Moser M, Joner M, Desmet W, Adriaenssens T, Neumann FJ, Gerschlick AH, Ten Berg JM, Lorenz M, Stark K. Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps. Blood. 2019;134(21):1859\u201372.","journal-title":"Blood"},{"issue":"3","key":"666_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0002-9149(83)90131-5","volume":"52","author":"JB Harley","year":"1983","unstructured":"Harley JB, Fauci AS, Gralnick HR. Noncardiovascular findings associated with heart disease in the idiopathic hypereosinophilic syndrome. Am J Cardiol. 1983;52(3):321\u20134.","journal-title":"Am J Cardiol"},{"issue":"10","key":"666_CR8","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1182\/blood.V83.10.2759.2759","volume":"83","author":"PF Weller","year":"1994","unstructured":"Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83(10):2759\u201379.","journal-title":"Blood"},{"issue":"2","key":"666_CR9","doi-asserted-by":"publisher","first-page":"H405","DOI":"10.1152\/ajpheart.00133.2019","volume":"317","author":"DR Prows","year":"2019","unstructured":"Prows DR, Klingler A, Gibbons WJ Jr, Homan SM, Zimmermann N. Characterization of a mouse model of hypereosinophilia-associated heart disease. Am J Physiol Heart Circ Physiol. 2019;317(2):H405\u201314. https:\/\/doi.org\/10.1152\/ajpheart.00133.2019 (Epub 2019 Jun 14).","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"666_CR10","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","volume":"146","author":"F Roufosse","year":"2020","unstructured":"Roufosse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, Gilson MJ, Bentley JH, Bradford ES, Yancey SW, Steinfeld J, Gleich GJ, HES Mepolizumab study group. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;146(6):1397\u2013405.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"666_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.iac.2020.07.001","volume":"40","author":"B Olivieri","year":"2020","unstructured":"Olivieri B, Tinazzi E, Caminati M, Lunardi C. Biologics for the treatment of allergic conditions: eosinophil disorders. Immunol Allergy Clin North Am. 2020;40(4):649\u201365. https:\/\/doi.org\/10.1016\/j.iac.2020.07.001.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"14","key":"666_CR12","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","volume":"380","author":"FL Kuang","year":"2019","unstructured":"Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med. 2019;380(14):1336\u201346.","journal-title":"N Engl J Med"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-022-00666-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-022-00666-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-022-00666-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T13:03:53Z","timestamp":1647954233000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-022-00666-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["666"],"URL":"https:\/\/doi.org\/10.1186\/s13223-022-00666-2","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"assertion":[{"value":"23 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent obtained from patient for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}